How is Petrelintide administered?
This describes how Petrelintide is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a once weekly schedule, generally over trial protocols. Specific dosing is individual and beyond general information, and human evidence for Petrelintide is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: Once weekly
- Cycle length: Trial protocols
- Half-life: ~10 days (acylated/lipidated)
References
- Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity — Zealand Pharma (press release via GlobeNewswire), March 5, 2026
- Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity — Roche (press release), March 5, 2026
- A Randomized, Double-Blind, Phase 2 Trial of Once-Weekly Petrelintide Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) — ClinicalTrials.gov, NCT06926842 (Sponsor: Zealand Pharma)
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Petrelintide
Last updated 2026-06-15.